FDAnews
www.fdanews.com/articles/95345-rta-402-shown-to-protect-animals-against-toxicities-of-standard-cancer-treatments

RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments

June 29, 2007

Reata Pharmaceuticals, Inc. announced the presentation of new preclinical data showing their lead anticancer agent, the Synthetic Triterpenoid RTA 402, is effective at protecting against common toxicities caused by traditional cancer treatments. This data was presented at the annual meeting of the Multinational Association of Supportive Care in Cancer (MASSC) in St. Gallen, Switzerland.
Businesswire